Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Belgium / NCT07159776
Starting soon Observational

Multiple Digital Biomarkers for Optimization of IBD Care

NCT07159776 · tracked via the Priya Life Science Belgium tracker
Sponsor
Imelda GI Clinical Research Center
Phase
Observational
Started
2025-09-08
Last updated
2025-09-08

Condition(s) studied

Crohn Disease (CD)Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)

Investigational drug(s) / intervention(s)

monitoring of wearable data, shopping data, biomarkers and patient reported outcomes

monitoring of wearable data, shopping data, biomarkers and patient reported outcomes: 1. All participants will receive a wearable device type Corsano Health Cardio watch 287-2 which is provided by the sponsor via Inovigate. Participants will be encouraged to wear the device 24h per day and need to wear the wearable device at least 12 hours per day, preferential during daytime. 2. All participants will receive a loyalty card (Xtra card Colruyt group) which is provided by the sponsor via Inovigate for food data capturing. The patient is requested to execute all grocery shopping at one of the Colruyt Group stores. He/she will always need to offer the loyalty card to the cashier prior to payment. The purchase receipt will then be automatically sent to the central food data repository at the sponsor set up for this study. Non-food or non-food related data will neither be captured nor stored during the trial. 3. biomarkers in blood and feaces will be monitored according to standard of care 4. patient reported outcomes will be monitored according to standard of care

Study summary

To develop digital biomarkers associated with disease activity of inflammatory bowel disease

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Males or females aged \> 18 years * Diagnosis of CD, UC or IBD-unspecified for at least 1 month * Treatment with conventional or advanced therapy for IBD at initiation of the study * The patient must have access to an email address * The patient must be willing to perform all the groceries shopping at any of the Colruyt Group stores during this study, using an Xtra card created by the study team. * Capacity to independently answer regular digital questionnaires * Capacity and willingness to use a smartphone and activity tracker Exclusion Criteria: * Planned extended (\> 1 month) overseas travel during the study period of 12 months, if internet access would be impossible, inconvenient or unaffordable during this time * Previous colectomy * Inability to communicate well with investigators or unable to comply with the study requirements * Significant medical condition interfering with physiological measurements trough a wearable device (heart failure, pacemaker or defibrillator) * Inclusion or planned inclusion in an interventional IBD-related clinical trial

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Imelda General Hospital Bonheiden Belgium

More Imelda GI Clinical Research Center trials in Belgium

Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context Recruiting

Other trials for the same condition

Personalized Exercise Coaching to Improve Quality of Life in Pediatric IBD Active, not recruiting
A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease Recruiting
Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context Recruiting
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis Active, not recruiting
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07159776 on ClinicalTrials.gov ↗ ← All trials in Belgium